Literature DB >> 7949714

Phase I results of pullback atherectomy for hemodialysis access.

R J Gray1, B L Dolmatch, K M Horton, M Billingham, A Aquino, C B Currier, J A Light.   

Abstract

PURPOSE: Balloon angioplasty and directional atherectomy frequently have short-lived results for stenoses associated with hemodialysis. Results are reported for a phase I trial of the pullback atherectomy catheter (PAC) for treatment of hemodialysis access-related stenoses. PATIENTS AND METHODS: Six intragraft and six venous stenoses in nine patients were treated with the PAC. Two lesions were treated with adjunctive balloon angioplasty, and two were treated with adjunctive directional atherectomy. Clinical and angiographic follow-up were obtained for all patients. All specimens were examined histologically.
RESULTS: Initial procedural success was achieved in 83% of stenoses (10 of 12). For intragraft stenoses, the 6-month primary patency was 60% (three of five) and the 6-month secondary patency was 80% (four of five). All six venous stenoses restenosed or thrombosed within 3 months. All specimens contained fibrous plaque or intimal hyperplasia. In addition, all six venous stenosis specimens contained media and two contained adventitia. Significant complications during treatment of venous stenoses included severe venous spasm in three and venous pseudoaneurysms in two. One PAC tip fracture occurred during treatment of an intragraft stenosis.
CONCLUSION: Pullback atherectomy is potentially safe and effective for intragraft stenoses; however, it is not safe or effective for venous stenoses.

Entities:  

Mesh:

Year:  1994        PMID: 7949714     DOI: 10.1016/s1051-0443(94)71557-8

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  1 in total

Review 1.  [Percutaneous mechanical atherectomy for treatment of peripheral arterial occlusive disease].

Authors:  A Buecker; P Minko; A Massmann; M Katoh
Journal:  Radiologe       Date:  2010-01       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.